Connect study teams, research sites and participants with practical manage randomization and trial supply workflows suited to the scale and complexity of clinical research in Mumbai.
Mumbai is a major clinical-research market. The source register snapshot lists 259 studies with Mumbai sites. Tata Memorial Centre and Tata Memorial Hospital are identified in the source as important research institutions. Centaur Pharmaceuticals’ LifeSan division reports BA/BE and Phase II–IV clinical research and multiple regulator inspections. ACTREC in nearby Navi Mumbai has clinical research and clinical pharmacology capabilities. Clinical research activity changes over time, so this page uses a September 2026 snapshot as market context rather than a permanent study count.
The wider Mumbai clinical-research ecosystem includes Tata Memorial Centre, Tata Memorial Hospital, ACTREC and Centaur Pharmaceuticals’ LifeSan clinical research operation. These organizations are cited as examples of the local research environment and are not eTrialTrack customers unless a documented customer relationship exists.
For organizations operating in Mumbai, the relevant technology question is not simply whether a digital platform is available, but whether it can support the operational requirements of the study. eTrialTrack RTSM / IWRS can be evaluated for workflows involving oncology and complex multicentre research, high-volume data capture, participant follow-up, site coordination and integration between study workflows. The product is designed to provide manage randomization and trial supply workflows through randomization, treatment assignment, eligibility rules, inventory, kit tracking and operational reporting. The exact configuration should be determined by protocol requirements, organizational procedures, user roles, integrations and implementation scope.
Organizations in Mumbai can evaluate eTrialTrack RTSM / IWRS when they need a practical workflow that can be configured around their study rather than a generic process. Relevant product capabilities include Randomization; Treatment Assignment; Eligibility Rules; Inventory Management; Kit and Supply Tracking; Site-Level Access; Supply Status Visibility; Audit Trails and Reporting. Where appropriate, the module can connect with other eTrialTrack capabilities to create a more coherent participant, site and data workflow.
A typical discussion for a Mumbai study can begin with study requirements, participant and site workflows, data responsibilities, user roles, integrations, implementation timelines and support expectations. From there, the relevant eTrialTrack capabilities can be configured and evaluated against the study requirements.
Tata Memorial Centre, Tata Memorial Hospital, ACTREC and Centaur Pharmaceuticals’ LifeSan clinical research operation. These names describe the broader market context only and should not be presented as customers, partners or users of eTrialTrack without documented evidence.
eTrialTrack RTSM / IWRS is a technology capability, not a substitute for the approved protocol, investigator responsibilities, ethics requirements, applicable regulations, quality procedures or clinical judgment. Product suitability should be assessed against the specific study and documented requirements.
For research teams in Mumbai, the RTSM/IWRS module fits specific roles and study situations — here's who it serves, what it supports, and when to adopt it.
eTrialTrack RTSM/IWRS supports controlled randomization and trial supply workflows through a structured digital environment. The system can bring together treatment assignment, inventory visibility, site access, eligibility rules, kit tracking and relevant audit information.
Yes — eTrialTrack is FDA 21 CFR Part 11, ICH-GCP, HIPAA and GDPR compliant, with complete audit trails and e-signatures accepted by Indian (CDSCO) and global regulators.
Most teams go live in 2-4 weeks, including configuration, validation support and team training in IST.
Absolutely — book a 30-minute guided walkthrough and we will tailor it to your Mumbai study setup and protocols.